Pharmaceuticals

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2021-10-09 03:07 6492

CStone presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021

SUZHOU, China, Oct. 8, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the data on the preclini...

2021-10-08 08:00 4803

Breakthrough for medtech pioneer: Syntellix receives product approval for India, opening up fast-growing market with 1.38 billion people

Syntellix CEO Claassen: "Greatest and most important success in the company's history" - Indian CDSCO grants approvals for five MAGNEZIX® product families - The Era of Magnesium for orthopaedics and traumatology now also begins in India - Subcontinent will be the world's most populous growth m...

2021-10-07 22:08 2963

Cambrex to Invest $30 Million to Expand Manufacturing Center of Excellence at High Point, NC Facility

EAST RUTHERFORD, N.J., Oct. 7, 2021 /PRNewswire/ -- Cambrex today announced that it is expanding its manufacturing center of excellence inHigh Point, NC. The $30+ million investment is designed to meet the continually growing demand for small molecule development and manufacturing services. The ...

2021-10-07 20:30 3690

Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis

LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com ), a Swiss-based, global biopharmaceutical company, andDexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptor...

2021-10-07 06:00 2873

Luciole Pharmaceuticals and Cyclica Announce Research Collaboration to Accelerate Discovery of Novel Medicines

NATICK, Mass. and TORONTO, Oct. 7, 2021 /PRNewswire/ -- Luciole Pharmaceuticals, a startup company focused on the discovery and development of small molecules that enhance the repair of oxidative damage to mitochondrial DNA (mtDNA), and Cyclica, the partner of choice for data-driven drug discovery...

2021-10-07 03:56 1993

ArisGlobal LifeSphere® MultiVigilance is selected by Asahi Kasei Pharma

MIAMI and TOKYO, Oct. 6, 2021 /PRNewswire/ -- Asahi Kasei Pharma Corp. has selectedLifeSphere® MultiVigilance as a new safety database with the purpose of building a system that supports efficiency, regulatory compliance, and global collaboration over the long term. In addition, Asahi Kasei Pharm...

2021-10-06 11:00 3218

Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH

ROSCREA, Ireland and FREIBURG, Germany, Oct. 5, 2021 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal ("GI") disorders, announced today that it has entered into a Licensing and C...

2021-10-05 20:10 4747

RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer

STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onOctober 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 20...

2021-10-05 19:14 1879

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS). Innodem's AI-powere...

2021-10-05 19:04 2097

NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, presented an update of its Pan-Coronavirus COVID-19 Drug Development Program at t...

2021-10-05 18:45 11468

Zuellig Pharma Receives EcoVadis Platinum Medal in 2021 For Sustainability

SINGAPORE, Oct. 5, 2021 /PRNewswire/ -- Zuellig Pharma, a leading healthcare services provider inAsia, has been awarded the Platinum Medal 2021 by sustainability ratings specialistEcoVadis . The award is the highest accolade to be awarded to a company for its sustainability...

2021-10-05 09:00 5469

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patien...

2021-10-04 21:24 12162

Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award

LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categ...

2021-10-04 15:00 2111

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health ...

2021-10-04 08:00 4713

CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021

* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...

2021-10-02 08:30 10410

Zantrene® kills melanoma cancer cells that overproduce FTO

* Zantrene® at low concentrations kills high FTO producing melanoma cancer cells * Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells * Results are highly supportive of future clinical trials in ...

2021-09-30 11:58 11358

Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, Sept. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-09-30 08:00 4311

Nanoform receives funding to solve challenges for global health

HELSINKI, Sept. 29, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation to assess the added value Nanoform's award-winning CESS® nanoparticle engineering technology can d...

2021-09-29 21:15 2239

Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, Sept. 29, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet ...

2021-09-29 17:44 4500